ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IMM Immupharma Plc

3.90
-0.405 (-9.41%)
Last Updated: 13:23:34
Delayed by 15 minutes
Immupharma Investors - IMM

Immupharma Investors - IMM

Share Name Share Symbol Market Stock Type
Immupharma Plc IMM London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.405 -9.41% 3.90 13:23:34
Open Price Low Price High Price Close Price Previous Close
4.01 3.90 4.25 4.305
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Top Investor Posts

Top Posts
Posted at 31/1/2025 10:43 by mcdermov
They say they have made a preclinical breakthrough but can't describe it for reasons of commercial confidentiality. It may never have application in humans.Anybody buying based on this limited amount of non-information is gambling. The track record of this company is poor when it comes treatment of investors.AVOID.
Posted at 30/1/2025 20:24 by kop202
I seem to remember Tim mugging off investors a 2/3 years ago.... Tim seems to think there is a fresh tranche of gullible investors ripe for rogering.
Posted at 15/1/2025 10:52 by putinaire
Re IMM see?

Obviously no traders here.

Just 'skilled' investors LOOOOL
Posted at 13/1/2025 11:05 by putinaire
Must be awful having to make a living scrubbing little cap toilets

Why don't you lot become investors re enter real markets? 😂
Posted at 10/1/2025 12:21 by putinaire
oh look. Amazing how a maker adjustment on the tick, plays with supposed 'investor minds' haha
Posted at 09/1/2025 18:54 by wigwammer
Eleven $1bn+ deals signed in 9 months. Thats not a long period of time, nor evidently has the number of deals diluted the value of each subsequent deal, nor are these deals likely to all be phase 3 (like p140). Most importantly, with a £15m market cap immupharma doesn't have to take much of the pie to prove highly lucrative for investors. Your questions are being answered pretty well. Time to jump in?
Posted at 09/1/2025 14:07 by bri15
Putinaire with the yank market closed there's a lot less investors looking in over there.
Posted at 09/1/2025 12:59 by lord loads of lolly
wigwammer -

1) Yes, I am still a holder & I hope to at least recoup my investment here still. That doesn't stop me being critical of the Directors' track record.

2) Yes, TM marched this tiny uk biotech all the way to completion of a phase 3. Only problem being, that phase 3 was a bungled trial which failed to meet any of its endpoints. All Tim could legitimately say at the end of it was that the drug was safe yet ineffective.

3) Yes, I prefer scientific evidence to TM's constant waffle. Look what happened at Incanthera. He implied investors were on the brink of huge riches there too. Then suddenly, news of a patent infringement claim came in. And the share price duly plummeted. And has yet to regain much of its huge recent losses since mid-November 2024.
Posted at 07/2/2024 14:49 by blackhorse23
https://www.alliancepharmaceuticals.com/investors/shareholder-centre/significant-shareholders/
Posted at 31/8/2023 08:23 by lord loads of lolly
Yup, it smacks of desperation when the RNS keeps trying to make out there'll be positive newsflow going forward. And that this in turn SHOULD lead to an improved share price. Let's just look at the past sharing agreements shall we? And I quote directly from the RNS:

"The Sharing Agreement is similar in structure to those undertaken by the Company with Lanstead in February 2016, June 2019, March 2020, December 2021 and August 2022 respectively. The first three of these arrangements have completed their settlement periods. The February 2016 agreement yielded a net gain to ImmuPharma of approximately £0.6 million more than originally subscribed by Lanstead. The June 2019 and March 2020 agreements yielded approximately £0.9 million and £1.0 million less than originally subscribed by Lanstead respectively. The fourth arrangement runs to March 2024 and is currently yielding approximately £1.1 million less than the pro rata amount originally subscribed by Lanstead on cumulative settlements to date. The fifth arrangement runs to August 2024 and is currently yielding approximately £0.3 million less than the pro rata amount originally subscribed by Lanstead on cumulative settlements to date."

So that's five agreements in total, one of which yielded a positive result (+ £0.6m approx). Currently the other four - of which two are already complete - have yielded a cumulative LOSS of £3.3m versus the current share price. WHAT A TRIUMPH!

Given the above, how many private investors are likely to beat a path to the Winterflood Retail Access Platform so they can subscribe to the Retail Offer? Answers on a postcard please. Clue: the answer may be a nice round figure. At least it can't be negative. Unlike the Sharing Agreement outcomes to date.

Your Recent History

Delayed Upgrade Clock